Glenmede Trust’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Glenmede Trust’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-404	Closed	-$5K	–	3107
2018 Q3	$5K	Buy	+404	New	+$6.36K	﹤0.01%	1401

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Glenmede Trust's CNCE Position: Q4 2018 in Review

Glenmede Trust sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2018, closing a stake of 404 shares — an estimated $5K sold.

Glenmede Trust first reported a position in CNCE in Q3 2018 and held it in 1 quarter. The position peaked at $5K in Q3 2018. 93 funds tracked by Wall St. Rank hold CNCE as of Q4 2018.

Glenmede Trust reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Glenmede Trust sold 404 Concert Pharmaceuticals, Inc. shares in Q4 2018, an estimated $5K.
Glenmede Trust first reported a position in Concert Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
Glenmede Trust's Concert Pharmaceuticals, Inc. position peaked at $5K in Q3 2018.
93 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2018.

Based on Glenmede Trust's 13F filing for Q4 2018, filed 14 Feb 2019.